QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
Log in
OTCMKTS:ALPMY

Astellas Pharma Stock Forecast, Price & News

$15.93
-0.27 (-1.67 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.89
Now: $15.93
$16.11
50-Day Range
$15.87
MA: $16.54
$17.41
52-Week Range
$12.48
Now: $15.93
$18.43
Volume100,548 shs
Average Volume82,251 shs
Market Capitalization$29.66 billion
P/E Ratio23.09
Dividend Yield1.79%
Beta0.63
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Astellas Pharma logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ALPMY
CUSIPN/A
CIKN/A
Phone813-3244-3000
Employees15,883
Year Founded1923

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.97 billion
Cash Flow$1.28 per share
Book Value$6.28 per share

Profitability

Net Income$1.80 billion

Miscellaneous

Outstanding Shares1,861,790,000
Market Cap$29.66 billion
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.67 out of 5 stars

Medical Sector

283rd out of 1,969 stocks

Pharmaceutical Preparations Industry

131st out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -
$15.93
-0.27 (-1.67 %)
(As of 03/4/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Astellas Pharma (OTCMKTS:ALPMY) Frequently Asked Questions

Is Astellas Pharma a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Astellas Pharma stock.
View analyst ratings for Astellas Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Astellas Pharma?

Wall Street analysts have given Astellas Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Astellas Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Astellas Pharma?

Astellas Pharma saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 64,700 shares, an increase of 462.6% from the January 28th total of 11,500 shares. Based on an average daily trading volume, of 147,700 shares, the short-interest ratio is currently 0.4 days.
View Astellas Pharma's Short Interest
.

When is Astellas Pharma's next earnings date?

Astellas Pharma is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Astellas Pharma
.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) released its quarterly earnings data on Friday, January, 29th. The company reported $0.31 earnings per share for the quarter. The firm earned $3.12 billion during the quarter. Astellas Pharma had a trailing twelve-month return on equity of 13.24% and a net margin of 11.03%.
View Astellas Pharma's earnings history
.

How has Astellas Pharma's stock price been impacted by COVID-19?

Astellas Pharma's stock was trading at $15.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALPMY shares have increased by 1.3% and is now trading at $15.93.
View which stocks have been most impacted by COVID-19
.

Is Astellas Pharma a good dividend stock?

Astellas Pharma pays an annual dividend of $0.29 per share and currently has a dividend yield of 1.79%. The dividend payout ratio of Astellas Pharma is 30.21%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Astellas Pharma will have a dividend payout ratio of 19.08% next year. This indicates that Astellas Pharma will be able to sustain or increase its dividend.
View Astellas Pharma's dividend history.

When did Astellas Pharma's stock split? How did Astellas Pharma's stock split work?

Shares of Astellas Pharma split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were issued to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of Astellas Pharma stock prior to the split would have 125 shares after the split.

Who are Astellas Pharma's key executives?

Astellas Pharma's management team includes the following people:
  • Mr. Kenji Yasukawa Ph.D., Pres, CEO & Representative Director (Age 61)
  • Mr. Naoki Okamura, Corp. Exec. VP, CFO, Chief Strategy Officer & Representative Director (LinkedIn Profile)
  • Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec.
  • Ms. Catherine Levitt, Gen. Counsel
  • Mr. Stig Ogata, VP of Corp. Communications
  • Ms. Collette Taylor, Sr. VP of HR (Age 58)
  • Chihiro Yokota, Sr. Corp. Exec. and Head of Japan/Asia Devel., Devel.
  • Dr. Charlotte M. E. Kremer M.D., Mba, Head of Medical Affairs & Exec. VP
  • Mr. Songlin Xue M.D., Ph.D., Head of Pharmacovigilance
  • Akihiko Iwai, Pres of Drug Discovery Research & Sr. Corp. Exec.

Who are some of Astellas Pharma's key competitors?

What is Astellas Pharma's stock symbol?

Astellas Pharma trades on the OTCMKTS under the ticker symbol "ALPMY."

How do I buy shares of Astellas Pharma?

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Astellas Pharma's stock price today?

One share of ALPMY stock can currently be purchased for approximately $15.93.

How much money does Astellas Pharma make?

Astellas Pharma has a market capitalization of $29.66 billion and generates $11.97 billion in revenue each year. The company earns $1.80 billion in net income (profit) each year or $0.96 on an earnings per share basis.

How many employees does Astellas Pharma have?

Astellas Pharma employs 15,883 workers across the globe.

Does Astellas Pharma have any subsidiaries?

The following companies are subsidiares of Astellas Pharma: Agensys, Astellas B.V, Astellas Farma Brasil Importaçáo e Distribuiçáo de Medicamentos Ltda., Astellas Farma Colombia SAS, Astellas Farma Limitada, Astellas Green Supply Inc., Astellas Innovation Management LLC, Astellas Institute for Regenerative Medicine, Astellas Ireland Co. Limited, Astellas Pharma, Astellas Pharma A.G., Astellas Pharma A/S, Astellas Pharma Australia Pty Ltd., Astellas Pharma B.V., Astellas Pharma Canada Inc., Astellas Pharma China Inc., Astellas Pharma Co. Limited, Astellas Pharma DMCC, Astellas Pharma Europe B.V., Astellas Pharma Europe Ltd., Astellas Pharma Ges.m.b.H, Astellas Pharma Global Development Inc., Astellas Pharma GmbH, Astellas Pharma Hong Kong Co. Ltd., Astellas Pharma India Private Limited, Astellas Pharma Kft., Astellas Pharma Korea Inc., Astellas Pharma Ltd., Astellas Pharma Malaysia Sdn. Bhd., Astellas Pharma Philippines Inc., Astellas Pharma S.A., Astellas Pharma S.A.S, Astellas Pharma S.p.A., Astellas Pharma Singapore Pte. Ltd., Astellas Pharma Sp.zo.o., Astellas Pharma Taiwan Inc., Astellas Pharma Tech Co. Ltd., Astellas Pharma US Inc., Astellas Pharma d.o.o., Astellas Pharma ilaç Ticaret ve Sanayi A.Ş., Astellas Pharma s.r.o, Astellas Pharmaceuticals AEBE, Astellas Research Institute of America LLC, Astellas US Holding Inc., Astellas US LLC, Astellas US Technologies Inc., Astellas Venture Management LLC, Audentes Therapeutics, Ganymed Pharmaceuticals, Iota Biosciences, JSC Astellas Pharma, Mitobridge, Nanna Therapeutics, OSI Pharmaceuticals, Ocata Therapeutics, Ogeda, P.T. Astellas Pharma Indonesia, Potenza Therapeutics, Quethera, The Representative Office of Astellas Pharma Singapore Pte. Ltd. in Vietnam, Universal Cells Inc., and Xyphos.

When was Astellas Pharma founded?

Astellas Pharma was founded in 1923.

What is Astellas Pharma's official website?

The official website for Astellas Pharma is www.astellas.com.

Where are Astellas Pharma's headquarters?

Astellas Pharma is headquartered at 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411.

How can I contact Astellas Pharma?

Astellas Pharma's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000.


This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.